Top Markets
Coin of the day
Neoleukin Therapeutics, Inc. Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc.

NLTX
株式のランク #26679
Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused... Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused on developing immune-based treatments for conditions such as cancer, inflammatory responses, and autoimmune diseases, utilizing its proprietary protein design technology. The company's leading investigational therapy is NL-201, a novel protein meticulously crafted to emulate the therapeutic effects of the IL-2/IL-15 cytokines. This product candidate is intended for the management of various malignancies, including renal cell carcinoma and melanoma. The organization, founded in 2003, was previously known as Aquinox Pharmaceuticals, Inc. before officially changing its name to Neoleukin Therapeutics, Inc. in August 2019. Its operations are based out of Seattle, Washington.
株価
$3.49
最終同期: 2023-12-19
時価総額
$38.68M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Neoleukin Therapeutics, Inc. (NLTX)

カテゴリー

Neoleukin Therapeutics, Inc.(NLTX)の利益
2026 時点の利益 TTM: 0
Neoleukin Therapeutics, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Neoleukin Therapeutics, Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。